Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Illumina HiSeq Sequencing on Breast cancer PDX samples

ABSTRACT: Illumina HiSeq Sequencing on Breast cancer PDX samples

PROVIDER: PRJNA454798 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7100770.fastq.gz	Fastqsanger.gz
	SRR7100780.fastq.gz	Fastqsanger.gz
	SRR7100771.fastq.gz	Fastqsanger.gz
	SRR7100781.fastq.gz	Fastqsanger.gz
	SRR7100772.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 19

Similar Datasets

Illumina HiSeq Sequencing on Breast cancer PDX samples

Project description:RNAseq was done on Breast cancer PDX samples uisng Library protocol =llumina TruSeq Stranded Total RNA Kit with Ribo-Zero Gold , HiSeq 50 Cycle Single-Read Sequencing v4

2019-03-01 | GSE113986 | GEO

RNAseq of Breast cancer PDX samples

Project description:RNAseq was done on Breast cancer PDX samples uisng Library protocol =llumina TruSeq Stranded Total RNA Kit with Ribo-Zero Gold , HiSeq 125 Cycle Paired-End Sequencing v4

2018-05-24 | GSE113476 | GEO

RNAseq of Breast cancer PDX samples

Project description:RNAseq of Breast cancer PDX samples

| PRJNA451206 | ENA

DSBSO-based XL-MS Analysis of Breast Cancer PDX Tissues to Delineate Protein Interaction Network in Clinical Samples

Project description:We applied our previously established Alkyne-A-DSBSO-based in vivo XL-MS analytical platform on two types of breast cancer PDX samples cross-linking. Coupled with the LC-MSn strategy, the experiments enable us to obtain information on cancer-related protein-protein interactions since experimenting on PDX models.

2024-03-20 | PXD046966 | Pride

Illumina HiSeq 4000 PE sequencing of Daphnia magna

Project description:Illumina HiSeq 4000 paired end sequencing of Daphnia magna clonal populations

| PRJEB41941 | ENA

Transcriptome analysis of Opium poppy using Illumina HiSeq X Ten platform [cultivars]

Project description:Purpose: Opium poppy is one of the most important medical plants and remains the only commercial resource of morphinan-based painkillers. However, little is known about its regulation mechanism in benzylisoquinoline alkaloids (BIAs) biosynthesis. Herein, the Transcriptome dataset of Opium poppy was constructed to identify the gene involved in its regulation mechanism in BIAs biosynthesis. Methods: Using Illumina HiSeq X Ten platform, 33 samples of Illumina transcriptome data from different tissues, growth phases and cultivars were constructed. Results: The high-quality transcripts were subsequent quantified with the short reads, and the expression of each unigenes among different samples was calculated by RPKM (the reads per kilobase per million mapped reads). Conclusions: These data provide a foundation of opium poppy transcriptome which may contribute to understand the regulation of BIAs biosynthesis.

2019-04-11 | GSE129567 | GEO

18 PDX of triple-negative breast cancer genotyped with SNP6 Affymetrix arrays

Project description:To characterize Homologous recombination deficiency (BRCAness) in triple-negative breast cancer PDX models genomic signature was utilized. After normalization using Genotyping Console we obtained absolute copy number profiles using the GAP software (Popova et al, Genome Biol, 2009). The number of Large-scale State Transitions (LSTs) was used to annotate PDX as BRCAness or not (Popova et al, Cancer Res 2012).

2020-01-01 | E-MTAB-8654 | biostudies-arrayexpress

22 PDX of triple-negative breast cancer genotyped with Affymetrix Cytoscan HD

Project description:To characterize Homologous recombination deficiency (BRCAness) in triple-negative breast cancer PDX models genomic signature was utilized. After normalization using ChAS we obtained absolute copy number profiles using the GAP software (Popova et al, Genome Biol, 2009). The number of Large-scale State Transitions (LSTs) was used to annotate PDX as BRCAness or not (Popova et al, Cancer Res 2012).

2020-01-01 | E-MTAB-8653 | biostudies-arrayexpress

Gene expression profiling of FFPE breast cancer samples [Illumina DASL WG platform]

Project description:The use of Affymetrix U133 2.0 Plus chips on FFPE samples when coupled with a qPCR-based sample pre-assessment step, yielded satisfactory results from the point of view of biological reliability. When compared with the Illumina DASL WG platform, specifically designed for degraded RNA, the data generated with the Affymetrix platform showed a wider interquartile range (1.32 vs 0.57, p<2.2x10-16) suggesting a superior discriminatory power within samples as indicated by the good agreement with the immunohistiochemically derived ER status. FFPE primary breast cancer samples profiled using Illumina DASL WG platform after RNA amplification with the Nugen WT-Ovation FFPE System

2015-02-25 | GSE51451 | GEO

Characterizing the Chemoresistant Ovarian Cancer Population using the Heterogeneous PDX

Project description:The patient-derived xenograft (PDX) model retains the heterogeneity of patient tumors, allowing a means to not only examine efficacy of a therapy across a population, but also study crucial aspects of cancer biology in response to treatment. Herein we describe the development and characterization of an ovarian-PDX model in order to study the development of chemoresistance. We demonstrate that PDX tumors are not simply composed of tumor-initiating cells, but recapitulate the original tumor’s heterogeneity, oncogene expression profiles, and clinical response to chemotherapy. Combined carboplatin/paclitaxel treatment of PDX tumors enriches the cancer stem cell populations, but persistent tumors are not entirely composed of these populations. RNA-Seq analysis of treated PDX tumors compared to untreated tumors demonstrates a consistently contrasting genetic profile after therapy, suggesting similar, but few, pathways are mediating chemoresistance. The pathways most significantly altered included Protein Kinase A signaling, GNRH signaling, and sphingosine-1-phosphate signaling. Pathways and genes identified by this methodology represent novel approaches to targeting the chemoresistant population in ovarian cancer 6 pairs of Patient-Derived Xenografts (PDX) were ananlyzed using RNA-seq for a total of 12 samples. Each pair consists of a treated and untreated PDX of ovarian cancer. Treated Ovarian cancer PDXs were treated with 4 weeks of a combination of carboplatin and taxol. RNA was isolated and converted to cDNA. RNA-seq was conductred on the Illumina HiSeq 2000 with 50 bp paired end sequencing

2015-06-17 | E-GEOD-58586 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data